SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 101 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,171,356 | -36.5% | 218,413 | -8.4% | 0.02% | -41.9% |
| Q2 2023 | $4,993,207 | +60.2% | 238,567 | +61.7% | 0.04% | +43.3% |
| Q1 2023 | $3,116,593 | +1245.7% | 147,566 | +1521.6% | 0.03% | +1400.0% |
| Q4 2022 | $231,595 | -13.9% | 9,100 | -26.0% | 0.00% | 0.0% |
| Q4 2021 | $269,000 | -81.4% | 12,300 | -83.7% | 0.00% | -86.7% |
| Q3 2021 | $1,445,000 | -29.5% | 75,600 | -36.7% | 0.02% | -31.8% |
| Q2 2021 | $2,050,000 | -26.4% | 119,401 | -4.1% | 0.02% | -35.3% |
| Q1 2021 | $2,784,000 | -20.3% | 124,502 | -20.8% | 0.03% | -27.7% |
| Q4 2020 | $3,495,000 | +1038.4% | 157,130 | +654.9% | 0.05% | +683.3% |
| Q3 2020 | $307,000 | – | 20,816 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |